Sugi Predict

Sugi Predict / Compounds / SCHEMBL17309478

SCHEMBL17309478

SCHEMBL17309478

CON(C)C(=O)[C@@H]1CCCN1C(C)=O

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 6/20 0.37
▸ CHRM4 P08173 6/20 0.37
▸ CHRM5 P08912 6/20 0.37
▸ CHRM1 P11229 6/20 0.37
▸ CHRM3 P20309 6/20 0.37
▸ POLB P06746 1/20 0.36
▸ RAB9A P51151 1/20 0.35
▸ CCR1 P32246 1/20 0.34
▸ DPP4 P27487 1/20 0.34
▸ PREP P48147 1/20 0.34
▸ FAP Q12884 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19065845 1.00 CHRM2 (0.37) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL6210297 0.87 RAB9A (0.38) POLBRAB9ACCR1
SCHEMBL2672951 0.87 RAB9A (0.38) POLBRAB9ACCR1
SCHEMBL2525150 0.87 RAB9A (0.38) POLBRAB9ACCR1
SCHEMBL7029219 0.82 CHRM2 (0.41) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL3257721 0.82 CPT2 (0.40) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL17941198 0.82 CPT2 (0.40) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL3089785 0.82 CPT2 (0.40) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL25395953 0.80 HSD17B10 (0.53) —
SCHEMBL1584759 0.80 HSD17B10 (0.53) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-05-07 — — US disclosed
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS INC (US) 2026-02-12 — — US disclosed
EP-4565579-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS Theras, Inc. (US) 2025-06-11 — — EP disclosed
WO-2024030633-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS THERAS, INC. (US) 2024-02-08 — — WO disclosed
CN-107027306-B 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-05-05 — — CN disclosed
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-02 — — US disclosed
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-02 — — US disclosed
US-20190010135-A1 Novel Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-10 — — US disclosed
US-10106515-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-10-23 — — US disclosed
EP-3148963-B1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2018-06-13 — — EP disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 — — US disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 — — US disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 — — US disclosed
WO-2015181186-A1 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106515-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors CXCR2, CXCR1, CXCR3 CHRM2 3600/4885CHRM4 3680/4885CHRM5 3985/4885
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 CHRM2 3706/4885CHRM4 3737/4885CHRM5 4113/4885
US-20260125386-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS CHRM2 4224/4885CHRM4 4471/4885CHRM5 4798/4885
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors CXCR2, CXCR1, CXCR3 CHRM2 3586/4885CHRM4 3697/4885CHRM5 3974/4885
US-20260042764-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS KRAS, NRAS, HRAS CHRM2 3607/4885CHRM4 4156/4885CHRM5 4417/4885
US-20190010135-A1 Novel Compounds CXCR2, CXCR1, CXCR3 CHRM2 2479/4885CHRM4 2390/4885CHRM5 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.